A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib

Official Title

A Proof of Concept Clinical Trial of the Combination Cediranib-Olaparib at the Time of Disease Progression on Olaparib in Ovarian Cancer


This is a phase 2 study (the second phase in testing a new drug or drug combination) to see how useful adding investigational drug cediranib to olaparib after disease progression on olaparib alone in patients with ovarian cancer.

Trial Description

Primary Outcome:

  • Percentage of patients whose cancer shrinks or disappears after treatment
Secondary Outcome:
  • Percentage of decrease in CA-125 levels after treatment
  • Mutation status of genes compared to response to treatment
  • Number of occurences per side effect and severity
  • Assess patient reported outcomes during treatment
Cediranib works by blocking (inhibiting) several specific proteins in cancer cells called the vascular endothelial growth factor (VEGF) receptors. These proteins are important in the formation of blood vessels to the tumour. It is believed that many tumours survive because the blood vessels on the tumours bring oxygen and nutrients to the cancer cells which enable them to grow. If the formation of the blood vessels is blocked, the tumour cells may die. Olaparib works by blocking protein called poly [adenosine diphosphate-ribose] polymerase (PARP). PARP is an important protein which tries to fix damaged deoxyribonucleic acid (DNA, molecules that contain important instructions for the development of cells). Many cancers are though develop from damaged DNA. By blocking PARP from fixing damaged DNA, the tumour cells may die. Adding cediranib to olaparib, and therefore blocking several different mechanisms for cancer growth, may stop tumour growth.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society